HALIFAX, Nova Scotia–(BUSINESS WIRE)–Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.
Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich, Theresa Matkovits, Rochelle Stenzler and Armand Balboni.
Voting results for each director are summarized below:
|
Name of Nominee |
Percentage of Votes For |
Percentage of Votes Against |
Percentage of Votes Withheld |
|
Ian Mortimer |
19,490,794 (98.42%) |
307,825 (1.55%) |
5,300 (0.03%) |
|
Brian Bloom |
16,812,009 (84.89%) |
2,985,610 (15.08%) |
6,300 (0.03%) |
|
Juergen Froehlich |
16,808,009 (84.87%) |
2,989,610 (15.10%) |
6,300 (0.03%) |
|
Theresa Matkovits |
19,489,794 (98.41%) |
307,825 (1.55%) |
6,300 (0.03%) |
|
Rochelle Stenzler |
19,490,794 (98.42%) |
307,825 (1.55%) |
5,300 (0.03%) |
|
Armand Balboni |
16,808,009 (84.87%) |
2,989,610 (15.10%) |
6,300 (0.03%) |
In addition to the election of the directors of the Company as noted above, the Shareholders:
- re-appointed PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration;
- approved amendments to the Company’s stock option plan to, inter alia, change the plan from a “fixed plan” to a rolling 10% plan; and
- approved the Company’s equity incentive plan.
The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company’s SEDAR profile at www.sedar.com
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, a broad-spectrum antifungal, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Contacts
Media Contact:
Danielle Raabe/APCO Worldwide
T: 1-646-717-9915
E: DRaabe@apcoworldwide.com
Investor Relations Contact:
Armand Balboni, CEO
Appili Therapeutics
Info@AppiliTherapeutics.com